Thermo Fisher Scientific (NYSE:TMO) Issues FY 2025 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 22.220-22.840 for the period, compared to the consensus earnings per share estimate of 22.332. The company issued revenue guidance of $43.6 billion-$44.2 billion, compared to the consensus revenue estimate of $43.7 billion. Thermo Fisher Scientific also updated its Q3 2025 guidance to 5.460-5.510 EPS.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. HSBC reaffirmed a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Argus decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Finally, Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research report on Thursday. Five analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Stock Performance

TMO traded up $3.58 during trading on Friday, hitting $478.61. The company's stock had a trading volume of 4,191,526 shares, compared to its average volume of 2,512,662. The business's 50 day simple moving average is $412.43 and its 200-day simple moving average is $470.68. The company has a quick ratio of 1.38, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a market cap of $180.67 billion, a PE ratio of 27.68, a P/E/G ratio of 2.25 and a beta of 0.77. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the company posted $5.37 earnings per share. As a group, sell-side analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.36%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Insider Activity

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president owned 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.33% of the company's stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

An institutional investor recently raised its position in Thermo Fisher Scientific stock. Revolve Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 491 shares of the medical research company's stock after purchasing an additional 20 shares during the period. Revolve Wealth Partners LLC's holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent reporting period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.